GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage ...

They also talk about the impact anti-vaxx misinformation has had on vaccine uptake in recent years and what impact COVID has had on that. Philip also discusses GSK’s recent mRNA vaccine research ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has ...

British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine ...

With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

LONDON, UK I 12, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal ...

In Australia, our process differs slightly and tends to take a little longer. The TGA’s website indicates applications for ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

GSK announced positive Phase II results for its mRNA seasonal influenza vaccine, showing strong immune responses against ...

GSK announced promising results from its phase two clinical trial for an mRNA-based seasonal flu vaccine on Thursday.

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

GSK had been developing mRNA flu and COVID-19 shots with its partner CureVac, but earlier this year announced it had gained full control of those assets. GSK also sees potential for a combined shot.